Sartorius Stedim Biotech Overview
- Year Founded
-
1978
- Status
-
Public
- Employees
-
9,961
- Stock Symbol
-
DIM
- Investments
-
13
- Share Price
-
$226.36
- (As of Tuesday Closing)
Sartorius Stedim Biotech General Information
Description
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. Its sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
Contact Information
Website
www.sartorius-stedim.comCorporate Office
- Zone Industrielle les Paluds
- Avenue de Jouques CS 91051
- 13781 Aubagne
- France
Corporate Office
- Zone Industrielle les Paluds
- Avenue de Jouques CS 91051
- 13781 Aubagne
- France
Sartorius Stedim Biotech Stock Performance
As of 13-May-2025, Sartorius Stedim Biotech’s stock price is $226.36. Its current market cap is $22B with 97.3M shares.
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $226.36 | $228.06 | $149.34 - $250.46 | $22B | 97.3M | 78.4K | $2.27 |
Sartorius Stedim Biotech Financials Summary
As of 31-Mar-2025, Sartorius Stedim Biotech has a trailing 12-month revenue of $3.07B.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 21,511,124 | 21,748,358 | 28,350,314 | 30,780,808 |
| Revenue | 3,067,749 | 3,008,235 | 3,003,300 | 3,672,236 |
| EBITDA | 740,287 | 705,096 | 811,016 | 1,398,576 |
| Net Income | 219,317 | 189,476 | 335,768 | 921,134 |
| Total Assets | 8,987,153 | 8,591,378 | 8,544,852 | 5,432,123 |
| Total Debt | 3,174,266 | 2,986,025 | 4,070,082 | 1,217,922 |
Sartorius Stedim Biotech Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Sartorius Stedim Biotech Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Sartorius Stedim Biotech Patents
Sartorius Stedim Biotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240209411-A1 | Method for sterility testing | Pending | 26-Apr-2021 | ||
| US-10947489-B2 | Bioreactor system and method | Active | 02-Jun-2015 | ||
| US-20180187140-A1 | Bioreactor system and method | Active | 02-Jun-2015 | ||
| EP-2621829-A1 | Detection of the integrity of a tight, closed, soft plastic pouch for receiving and protecting a product or a biopharmaceutical device | Inactive | 30-Sep-2010 | ||
| EP-2443044-A1 | Bag with an integrated tamper indicator, method for making such a bag, and method for using same | Active | 18-Jun-2009 | B65D79/02 |
Sartorius Stedim Biotech Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Sartorius Stedim Biotech Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Sartorius Stedim Biotech Investments & Acquisitions (13)
Sartorius Stedim Biotech’s most recent deal was a Early Stage VC with ViroCell Biologics for . The deal was made on 14-Aug-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| ViroCell Biologics | 14-Aug-2023 | Early Stage VC | Drug Discovery | ||
| ViroCell Biologics | 15-Nov-2022 | Early Stage VC | Drug Discovery | ||
| Xell | 29-Jul-2021 | Merger/Acquisition | Pharmaceuticals | ||
| Novasep (Chromatography Equipment Division) | 07-Feb-2021 | Merger/Acquisition | Other Pharmaceuticals and Biotechnology | ||
| WaterSep BioSeparations | 09-Dec-2020 | Merger/Acquisition | Other Commercial Products |
Sartorius Stedim Biotech ESG
Risk Overview
Risk Rating
Updated September, 14, 2024
14.94 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,631
Rank
Percentile
Pharmaceuticals
Industry
of 843
Rank
Percentile
Laboratory Equipment and Services
Subindustry
of 59
Rank
Percentile
Sartorius Stedim Biotech Affiliates
Subsidiaries (7)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Sartorius Stedim Fmt | Aubagne, France | 2012 | |
| Xell | Schloß Holte-Stukenbrock, Germany | 2009 | |
| Sartorius Stedim Belgium | Woluwe-Saint-Lambert, Belgium | 2007 | |
| BioOutsource | Glasgow, United Kingdom | 2007 | |
| Sartorius Stedim Poland | Kostrzyn, Poland | 2007 |
Sartorius Stedim Biotech FAQs
-
When was Sartorius Stedim Biotech founded?
Sartorius Stedim Biotech was founded in 1978.
-
Where is Sartorius Stedim Biotech headquartered?
Sartorius Stedim Biotech is headquartered in Aubagne, France.
-
What is the size of Sartorius Stedim Biotech?
Sartorius Stedim Biotech has 9,961 total employees.
-
What industry is Sartorius Stedim Biotech in?
Sartorius Stedim Biotech’s primary industry is Other Pharmaceuticals and Biotechnology.
-
Is Sartorius Stedim Biotech a private or public company?
Sartorius Stedim Biotech is a Public company.
-
What is Sartorius Stedim Biotech’s stock symbol?
The ticker symbol for Sartorius Stedim Biotech is DIM.
-
What is the current stock price of Sartorius Stedim Biotech?
As of 13-May-2025 the stock price of Sartorius Stedim Biotech is $226.36.
-
What is the current market cap of Sartorius Stedim Biotech?
The current market capitalization of Sartorius Stedim Biotech is $22B.
-
What is Sartorius Stedim Biotech’s current revenue?
The trailing twelve month revenue for Sartorius Stedim Biotech is $3.07B.
-
What is Sartorius Stedim Biotech’s annual earnings per share (EPS)?
Sartorius Stedim Biotech’s EPS for 12 months was $2.27.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
